User menu

Safety and efficacy of natalizumab in Belgian multiple sclerosis patients: subgroup analysis of the natalizumab observational program

Bibliographic reference Van Pesch, Vincent ; Bartholomé, Emmanuel ; Bissay, Véronique ; Bouquiaux, Olivier ; Bureau, Michel ; et. al. Safety and efficacy of natalizumab in Belgian multiple sclerosis patients: subgroup analysis of the natalizumab observational program. In: Acta Neurologica Belgica, Vol. 114, no.3, p. 167-178 (2014)
Permanent URL http://hdl.handle.net/2078.1/153416
  1. Polman Chris H., O'Connor Paul W., Havrdova Eva, Hutchinson Michael, Kappos Ludwig, Miller David H., Phillips J. Theodore, Lublin Fred D., Giovannoni Gavin, Wajgt Andrzej, Toal Martin, Lynn Frances, Panzara Michael A., Sandrock Alfred W., A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis, 10.1056/nejmoa044397
  2. Rudick Richard A., Stuart William H., Calabresi Peter A., Confavreux Christian, Galetta Steven L., Radue Ernst-Wilhelm, Lublin Fred D., Weinstock-Guttman Bianca, Wynn Daniel R., Lynn Frances, Panzara Michael A., Sandrock Alfred W., Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis, 10.1056/nejmoa044396
  3. Sandborn William J., Colombel Jean Frédéric, Enns Roberts, Feagan Brian G., Hanauer Stephen B., Lawrance Ian C., Panaccione Remo, Sanders Martin, Schreiber Stefan, Targan Stephan, van Deventer Sander, Goldblum Ronald, Despain Darrin, Hogge Gary S., Rutgeerts Paul, Natalizumab Induction and Maintenance Therapy for Crohn's Disease, 10.1056/nejmoa043335
  4. Phan-Ba Rémy, Lommers Emilie, Tshibanda Luaba, Calay Philippe, Dubois Bernard, Moonen Gustave, Clifford David, Belachew Shibeshih, MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy: Figure 1, 10.1136/jnnp-2011-300511
  5. Butzkueven H., Kappos L., Pellegrini F., Trojano M., Wiendl H., Patel R. N., Zhang A., Hotermans C., Belachew S., , Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results, 10.1136/jnnp-2013-306936
  6. Piehl Fredrik, Holmén C., Hillert J., Olsson T., Swedish natalizumab (Tysabri) multiple sclerosis surveillance study, 10.1007/s10072-010-0345-y
  7. Oturai A. B., Koch-Henriksen N., Petersen T., Jensen P. E. H., Sellebjerg F., Sorensen P. S., Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study, 10.1111/j.1468-1331.2008.02517.x
  8. Melin A., Outteryck O., Collongues N., Zéphir H., Fleury M. C., Blanc F., Lacour A., Ongagna J. C., Berteloot A. S., Vermersch P., Sèze J., Effect of natalizumab on clinical and radiological disease activity in a French cohort of patients with relapsing-remitting multiple sclerosis, 10.1007/s00415-011-6339-8
  9. Outteryck Olivier, Ongagna J.-C., Zéphir H., Fleury M.-C., Lacour A., Blanc F., Vermersch P., Sèze J., Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice, 10.1007/s00415-009-5294-0
  10. Fernández O., Oreja-Guevara C., Arroyo R., Izquierdo G., Pérez J. L., Montalban X., Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study, 10.1007/s00415-012-6414-9
  11. Salviati Alessandro, Burlina Alessandro P., Borsini Walter, Nervous system and Fabry disease, from symptoms to diagnosis: damage evaluation and follow-up in adult patients, enzyme replacement, and support therapy, 10.1007/s10072-009-0211-y
  12. Prosperini L et al (2010) Natalizumab treatment in multiple sclerosis: the experience of S. Andrea MS Centre in Rome. Neurol Sci 31(3):303–307
  13. Putzki N., Yaldizli O., Mäurer M., Cursiefen S., Kuckert S., Klawe C., Maschke M., Tettenborn B., Limmroth V., Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries : Natalizumab in second line therapy paper statistics, 10.1111/j.1468-1331.2009.02728.x
  14. Holmén Carolina, Piehl Fredrik, Hillert Jan, Fogdell-Hahn Anna, Lundkvist Malin, Karlberg Elin, Nilsson Petra, Dahle Charlotte, Feltelius Nils, Svenningsson Anders, Lycke Jan, Olsson Tomas, A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis, 10.1177/1352458510394701
  15. Bloomgren Gary, Richman Sandra, Hotermans Christophe, Subramanyam Meena, Goelz Susan, Natarajan Amy, Lee Sophia, Plavina Tatiana, Scanlon James V., Sandrock Alfred, Bozic Carmen, Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy, 10.1056/nejmoa1107829
  16. Kappos L et al (2012) Long-term safety and efficacy and association between baseline treatment history and postbaseline relapses in multiple sclerosis patients treated with natalizumab in the TYSABRI(R) observational program (TOP) (P04.134). Neurology 78:P04.134
  17. Oral presentations, 10.1177/1352458512459018
  18. Hutchinson M., , Kappos L., Calabresi P. A., Confavreux C., Giovannoni G., Galetta S. L., Havrdova E., Lublin F. D., Miller D. H., O’Connor P. W., Phillips J. T., Polman C. H., Radue E.-W., Rudick R. A., Stuart W. H., Wajgt A., Weinstock-Guttman B., Wynn D. R., Lynn F., Panzara M. A., The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL, 10.1007/s00415-009-0093-1